查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1726298

全球间质干细胞治疗市场：市场规模、份额、趋势分析（按类型、原材料、适应症和地区）、细分市场预测（2025 年至 2030 年）

Mesenchymal Stem Cell Therapy Market Size, Share & Trends Analysis Report By Type (Autologous, Allogenic), By Source (Bone Marrow, Umbilical Cord, Adipose), By Disease Indication, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

间质干细胞治疗市场的成长与趋势：

根据Grand View Research, Inc.的最新报告，全球间质干细胞治疗市场规模预计到2030年将达到2.966亿美元，2025年至2030年期间的复合年增长率为23.5%。

间质干细胞(MSC) 治疗市场由于几个关键因素而正在经历显着成长。其中一个主要驱动因素是心血管疾病、糖尿病、自体免疫疾病和整形外科疾病等慢性疾病的盛行率不断上升。 MSCs 具有独特的再生和免疫调节特性，使其成为治疗这些慢性疾病的有希望的候选药物。它们能够分化成各种细胞类型并促进组织修復，这增加了人们对基于 MSC 的疗法的兴趣。随着全球慢性病负担不断增加，对 MSC 疗法等创新治疗方法的需求预计将相应增长。

推动 MSC 治疗市场发展的另一个关键因素是人们对再生医学的认识不断提高和进步。再生医学专注于修復和替换受损的细胞、组织和器官，其中 MSCs 因其多功能而发挥关键作用。该领域的临床试验和研究活动激增，旨在利用 MSCs 的潜力用于各种治疗应用。人们对此类再生解决方案的兴趣日益浓厚，促进了 MSC 治疗市场的扩张。

技术进步也有助于推动 MSC 治疗市场向前发展。干细胞分离、培养和操作技术的创新正在提高 MSC 治疗的效率和有效性。依照良好生产规范 (GMP) 开发产品可确保始终如一的品质和安全，从而促进更广泛的临床应用。这些技术进步不仅改善了现有的治疗方法，而且为新的治疗应用铺平了道路，增加了对 MSC 治疗的整体需求。

此外，MSC 治疗市场也受益于支持性的法规环境和对干细胞研究的资金增加。政府和研究机构正在实施政策，鼓励临床试验并加速新干细胞疗法的核准。这种良好的环境促进了创新，使得 MSC 疗法能够高效开发和商业化。此外，公共和私营部门的投资活性化正在刺激研究计划和合作，确保新的 MSC 疗法的稳定供应。

间质干细胞治疗市场：分析概述

  • 根据类型，同种异体预计将在 2024 年占据整体市场主导地位，占据 73.83% 的最大收益占有率，并预计在预测期内以最快的复合年增长率增长。同种异体间质干细胞(MSC) 在治疗中的应用日益广泛，推动了市场的成长，因为它们可以从健康捐赠者那里获取并应用于多名患者。这减少了对个人化细胞采购的需求，使治疗更加便捷且更具成本效益。
  • 以原料计算，脂肪部分将在 2024 年占据整个市场的主导地位，收益占有率最大，为 37.71%，预计在预测期内将以最快的复合年增长率增长。脂肪干细胞 (ADSC) 市场因其高产量和多功能不断扩大，为各种慢性和与老龄化相关的疾病提供了有效的治疗方法。细胞处理和製造技术的进步提高了 ADSC 疗法的可及性和可用性，进一步推动了市场成长。
  • 2024 年，整形外科和肌肉骨骼疾病领域按适应症占据第二大市场占有率（25.56%）。随着全球肌肉骨骼疾病负担的增加，整形外科继续成为 MSC 治疗的主要成长领域。
  • 2024 年，亚太地区占据了最大的市场占有率，为 71.56%。在政府支持、医疗保健投资增加以及当地临床活动活性化的推动下，市场正在快速成长。

目录

第一章 分析方法与范围

第二章执行摘要

第三章 市场驱动因素、趋势与范围

  • 市场区隔和范围
  • 市场联动展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制分析
  • 产业分析工具
    • SWOT分析；按因素（政治、法律、经济、技术）
    • 波特五力分析
    • COVID-19影响分析

间质干细胞治疗市场：按类型分類的业务分析

  • 细分仪表板
  • 全球间质干细胞治疗趋势分析
  • 全球间质干细胞治疗市场规模及趋势分析（2018-2030）
  • 自体移植
  • 同种异体

间质干细胞治疗市场：原料业务分析

  • 细分仪表板
  • 全球间质干细胞治疗趋势分析
  • 全球间质干细胞治疗市场规模及趋势分析（2018-2030）
  • 骨髓
  • 脐带
  • 胖的
  • 其他成分

间质干细胞治疗市场：依适应症进行的商业分析

  • 细分仪表板
  • 全球间质干细胞治疗趋势分析
  • 全球间质干细胞治疗市场规模及趋势分析（2018-2030）
  • 整形外科和肌肉骨骼疾病
  • 心血管疾病
  • 神经系统和中枢神经系统疾病
  • 血液/免疫疾病
  • 其他适应症

第七章间间质干细胞治疗市场：区域评估与趋势分析（按类型、来源和适应症）

  • 区域仪表板
  • 市场规模预测及趋势分析（2018-2030年）
  • 北美洲
    • 美国
  • 欧洲
    • 英国
    • 德国
  • 亚太地区
    • 日本
    • 韩国
  • 其他国家

第八章 竞争态势

  • 公司/竞争对手分类
  • 战略地图
  • 公司地位分析（2024年）
  • 公司简介/上市公司
    • MEDIPOST, Inc.
    • PHARMICELL Co., Ltd
    • Antrogen
    • CORESTEMCHEMON Inc.
    • NIPRO Corporation
    • STEMPEUTICS RESEARCH PVT LTD
    • JCR Pharmaceuticals Co Ltd
    • Mesoblast, Inc.
    • Cell Tech Pharmed
    • HOLOSTEM Srl
    • Takeda Pharmaceutical Company Limited
Product Code: GVR-4-68040-554-9

Mesenchymal Stem Cell Therapy Market Growth & Trends:

The global mesenchymal stem cell therapy market size is anticipated to reach USD 296.6 million by 2030 and is projected to grow at a CAGR of 23.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. The mesenchymal stem cell (MSC) therapy market is experiencing significant growth, driven by several key factors. One major driver is the increasing prevalence of chronic diseases such as cardiovascular conditions, diabetes, autoimmune disorders, and orthopedic ailments. MSCs possess unique regenerative and immunomodulatory properties, making them promising candidates for treating these chronic conditions. Their ability to differentiate into various cell types and promote tissue repair has spurred interest in MSC-based therapeutics. As the global burden of chronic illnesses continues to rise, the demand for innovative treatments like MSC therapy is expected to grow correspondingly.

Another significant factor propelling the MSC therapy market is the growing awareness and advancement in regenerative medicine. Regenerative medicine focuses on repairing or replacing damaged cells, tissues, or organs, and MSCs play a crucial role due to their multipotent nature. The field has witnessed a surge in clinical trials and research activities, aiming to harness the potential of MSCs in various therapeutic applications. This heightened focus on regenerative solutions is contributing to the expansion of the MSC therapy market.

Technological advancements have also been instrumental in driving the MSC therapy market forward. Innovations in stem cell isolation, culture, and manipulation techniques have enhanced the efficiency and effectiveness of MSC therapies. The development of Good Manufacturing Practice (GMP)-compliant products ensures consistent quality and safety, facilitating broader clinical adoption. These technological strides not only improve existing treatments but also open new avenues for therapeutic applications, thereby increasing the overall demand for MSC therapies.

Furthermore, the MSC therapy market benefits from a supportive regulatory environment and increased funding for stem cell research. Governments and institutions are implementing policies that facilitate clinical trials and expedite approvals for new stem cell treatments. This favorable landscape encourages innovation and allows for the efficient development and commercialization of MSC therapies. Additionally, heightened investment from both public and private sectors fosters research initiatives and collaborations, ensuring a steady pipeline of new MSC treatments.

Mesenchymal Stem Cell Therapy Market Report Highlights:

  • Based on type, allogenic segment dominated the overall market with the largest revenue share of 73.83% in 2024 and is expected to grow at the fastest CAGR during the forecast period. The increasing use of allogenic mesenchymal stem cells (MSCs) in therapy is driving market growth due to their ability to be sourced from healthy donors and applied to multiple patients. This reduces the need for personalized cell sourcing, making treatments more accessible and cost-effective.
  • Based on source, the adipose segment dominated the overall market with the largest revenue share of 37.71% in 2024 and is expected to grow at the fastest CAGR during the forecast period. The market for adipose-derived stem cells (ADSCs) is expanding due to their high yield and multipotency, offering effective treatments for various chronic diseases and age-related conditions. Ongoing advancements in cell processing and manufacturing techniques are enhancing the accessibility and affordability of ADSC therapies, further driving market growth.
  • In 2024, orthopedic and musculoskeletal disorders segment held the second-largest market share of 25.56% in the disease indication segment. As the burden of musculoskeletal diseases rises globally, the orthopedic segment continues to be a major growth area within the MSC therapy landscape.
  • Asia Pacific accounted for the largest market share of 71.56% in 2024. The market is experiencing rapid growth fueled by government support, rising healthcare investments, and increasing local clinical activity.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Type
    • 1.2.2. Source
    • 1.2.3. Disease Indication
  • 1.3. Information analysis
  • 1.4. Market formulation & data visualization
  • 1.5. Data validation & publishing
  • 1.6. Information Procurement
    • 1.6.1. Primary Research
  • 1.7. Information or Data Analysis
  • 1.8. Market Formulation & Validation
  • 1.9. Market Model
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
      • 3.3.1.1. Broad Therapeutic Potential Across Multiple Diseases
      • 3.3.1.2. Advancements in Cell Culture & Manufacturing Technologies
    • 3.3.2. Market Restraint Analysis
      • 3.3.2.1. Stringent Regulatory Frameworks
  • 3.4. Industry Analysis Tools
    • 3.4.1. SWOT Analysis; By Factor (Political & Legal, Economic and Technological)
    • 3.4.2. Porter's Five Forces Analysis
    • 3.4.3. COVID-19 Impact Analysis

Chapter 4. Mesenchymal Stem Cell Therapy Market: Type Business Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Mesenchymal Stem Cell Therapy Movement Analysis
  • 4.3. Global Mesenchymal Stem Cell Therapy Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 4.4. Autologous
    • 4.4.1. Global Autologous Market, 2018 - 2030 (USD Million)
  • 4.5. Allogenic
    • 4.5.1. Global Allogenic Market, 2018 - 2030 (USD Million)

Chapter 5. Mesenchymal Stem Cell Therapy Market: Source Business Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Mesenchymal Stem Cell Therapy Movement Analysis
  • 5.3. Global Mesenchymal Stem Cell Therapy Market Size & Trend Analysis, by Source, 2018 to 2030 (USD Million)
  • 5.4. Bone Marrow
    • 5.4.1. Global Bone Marrow Market, 2018 - 2030 (USD Million)
  • 5.5. Umbilical Cord
    • 5.5.1. Global Umbilical Cord Market, 2018 - 2030 (USD Million)
  • 5.6. Adipose
    • 5.6.1. Global Adipose Market, 2018 - 2030 (USD Million)
  • 5.7. Others Sources
    • 5.7.1. Global Others Sources Market, 2018 - 2030 (USD Million)

Chapter 6. Mesenchymal Stem Cell Therapy Market: Disease Indication Business Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Mesenchymal Stem Cell Therapy Movement Analysis
  • 6.3. Global Mesenchymal Stem Cell Therapy Market Size & Trend Analysis, by Disease Indication, 2018 to 2030 (USD Million)
  • 6.4. Orthopedic and Musculoskeletal Disorders
    • 6.4.1. Global Orthopedic and Musculoskeletal Disorders Market, 2018 - 2030 (USD Million)
  • 6.5. Cardiovascular Diseases
    • 6.5.1. Global Cardiovascular Diseases Market, 2018 - 2030 (USD Million)
  • 6.6. Neurological and CNS Disorders
    • 6.6.1. Global Neurological and CNS Disorders Market, 2018 - 2030 (USD Million)
  • 6.7. Hematological / Immune Disorders
    • 6.7.1. Global Hematological / Immune Disorders Market, 2018 - 2030 (USD Million)
  • 6.8. Others Indications
    • 6.8.1. Global Others Indications Market, 2018 - 2030 (USD Million)

Chapter 7. Mesenchymal Stem Cell Therapy Market: Regional Estimates & Trend Analysis by Type, Source, Disease Indication

  • 7.1. Regional Dashboard
  • 7.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
  • 7.3. North America
    • 7.3.1. North America Mesenchymal stem cell therapy market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Competitive Scenario
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. U.S. Mesenchymal stem cell therapy market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. Europe Mesenchymal stem cell therapy market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. UK
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. UK Mesenchymal stem cell therapy market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Germany
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Germany Mesenchymal stem cell therapy market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Asia Pacific Mesenchymal stem cell therapy market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Japan
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Japan Mesenchymal stem cell therapy market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. South Korea
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. South Korea Mesenchymal stem cell therapy market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Rest of World
    • 7.6.1. Rest of World Mesenchymal Stem Cell Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company/Competition Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Position Analysis, 2024
  • 8.4. Company Profiles/Listing
    • 8.4.1. MEDIPOST, Inc.
      • 8.4.1.1. Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Strategic Initiatives
    • 8.4.2. PHARMICELL Co., Ltd
      • 8.4.2.1. Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Strategic Initiatives
    • 8.4.3. Antrogen
      • 8.4.3.1. Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Strategic Initiatives
    • 8.4.4. CORESTEMCHEMON Inc.
      • 8.4.4.1. Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Strategic Initiatives
    • 8.4.5. NIPRO Corporation
      • 8.4.5.1. Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Strategic Initiatives
    • 8.4.6. STEMPEUTICS RESEARCH PVT LTD
      • 8.4.6.1. Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Strategic Initiatives
    • 8.4.7. JCR Pharmaceuticals Co Ltd
      • 8.4.7.1. Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Strategic Initiatives
    • 8.4.8. Mesoblast, Inc.
      • 8.4.8.1. Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Strategic Initiatives
    • 8.4.9. Cell Tech Pharmed
      • 8.4.9.1. Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Strategic Initiatives
    • 8.4.10. HOLOSTEM S.r.l.
      • 8.4.10.1. Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Strategic Initiatives
    • 8.4.11. Takeda Pharmaceutical Company Limited
      • 8.4.11.1. Overview
      • 8.4.11.2. Financial Performance
      • 8.4.11.3. Product Benchmarking
      • 8.4.11.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global mesenchymal stem cell therapy market, by type, 2018 - 2030 (USD Million)
  • Table 4 Global mesenchymal stem cell therapy market, by source, 2018 - 2030 (USD Million)
  • Table 5 Global mesenchymal stem cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 6 Global mesenchymal stem cell therapy market, by region, 2018 - 2030 (USD Million)
  • Table 7 North America mesenchymal stem cell therapy market, by country, 2018 - 2030 (USD Million)
  • Table 8 North America mesenchymal stem cell therapy market, by type, 2018 - 2030 (USD Million)
  • Table 9 North America mesenchymal stem cell therapy market, by source, 2018 - 2030 (USD Million)
  • Table 10 North America mesenchymal stem cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 11 U.S. mesenchymal stem cell therapy market, by type, 2018 - 2030 (USD Million)
  • Table 12 U.S. mesenchymal stem cell therapy market, by source, 2018 - 2030 (USD Million)
  • Table 13 U.S. mesenchymal stem cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 14 Europe mesenchymal stem cell therapy market, by country, 2018 - 2030 (USD Million)
  • Table 15 Europe mesenchymal stem cell therapy market, by type, 2018 - 2030 (USD Million)
  • Table 16 Europe mesenchymal stem cell therapy market, by source, 2018 - 2030 (USD Million)
  • Table 17 Europe mesenchymal stem cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 18 UK mesenchymal stem cell therapy market, by type, 2018 - 2030 (USD Million)
  • Table 19 UK mesenchymal stem cell therapy market, by source, 2018 - 2030 (USD Million)
  • Table 20 UK mesenchymal stem cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 21 Germany mesenchymal stem cell therapy market, by type, 2018 - 2030 (USD Million)
  • Table 22 Germany mesenchymal stem cell therapy market, by source, 2018 - 2030 (USD Million)
  • Table 23 Germany mesenchymal stem cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 24 Asia Pacific mesenchymal stem cell therapy market, by country, 2018 - 2030 (USD Million)
  • Table 25 Asia Pacific mesenchymal stem cell therapy market, by type, 2018 - 2030 (USD Million)
  • Table 26 Asia Pacific mesenchymal stem cell therapy market, by source, 2018 - 2030 (USD Million)
  • Table 27 Asia Pacific mesenchymal stem cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 28 Japan mesenchymal stem cell therapy market, by type, 2018 - 2030 (USD Million)
  • Table 29 Japan mesenchymal stem cell therapy market, by source, 2018 - 2030 (USD Million)
  • Table 30 Japan mesenchymal stem cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 31 South Korea mesenchymal stem cell therapy market, by type, 2018 - 2030 (USD Million)
  • Table 32 South Korea mesenchymal stem cell therapy market, by source, 2018 - 2030 (USD Million)
  • Table 33 South Korea mesenchymal stem cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 34 Rest of World mesenchymal stem cell therapy market, by country, 2018 - 2030 (USD Million)
  • Table 35 Rest of World mesenchymal stem cell therapy market, by type, 2018 - 2030 (USD Million)
  • Table 36 Rest of World mesenchymal stem cell therapy market, by source, 2018 - 2030 (USD Million)
  • Table 37 Rest of World mesenchymal stem cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 38 Participant's overview
  • Table 39 Financial performance
  • Table 40 Key companies undergoing expansions
  • Table 41 Key companies undergoing acquisitions
  • Table 42 Key companies undergoing collaborations
  • Table 43 Key companies launching new products
  • Table 44 Key companies undertaking other strategies

List of Figures

  • Fig. 1 Mesenchymal stem cell therapy market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Segment snapshot
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Parent market outlook
  • Fig. 13 Related/ancillary market outlook
  • Fig. 14 Genomics - Industry value chain analysis
  • Fig. 15 Mesenchymal stem cell therapy market driver analysis
  • Fig. 16 Mesenchymal stem cell therapy market restraint analysis
  • Fig. 17 Mesenchymal stem cell therapy market: Porter's analysis
  • Fig. 18 Mesenchymal stem cell therapy market: Type outlook and key takeaways
  • Fig. 19 Mesenchymal stem cell therapy market: Type market share analysis, 2023 - 2030
  • Fig. 20 Global mesenchymal stem cell therapy by autologous market, 2018 - 2030 (USD Million)
  • Fig. 21 Global mesenchymal stem cell therapy by allogenic market, 2018 - 2030 (USD Million)
  • Fig. 22 Mesenchymal stem cell therapy market: Source outlook and key takeaways
  • Fig. 23 Mesenchymal stem cell therapy market: Source market share analysis, 2023 - 2030
  • Fig. 24 Global mesenchymal stem cell therapy by umbilical cord market, 2018 - 2030 (USD Million)
  • Fig. 25 Global mesenchymal stem cell therapy by adipose market, 2018 - 2030 (USD Million)
  • Fig. 26 Global mesenchymal stem cell therapy by other sources market, 2018 - 2030 (USD Million)
  • Fig. 27 Mesenchymal stem cell therapy market: Disease indication outlook and key takeaways
  • Fig. 28 Mesenchymal stem cell therapy market: Disease indication market share analysis, 2023 - 2030
  • Fig. 29 Global mesenchymal stem cell therapy by orthopedic and musculoskeletal disorders market, 2018 - 2030 (USD Million)
  • Fig. 30 Global mesenchymal stem cell therapy by cardiovascular diseases market, 2018 - 2030 (USD Million)
  • Fig. 31 Global mesenchymal stem cell therapy by neurological and CNS disorders market, 2018 - 2030 (USD Million)
  • Fig. 32 Global mesenchymal stem cell therapy by hematological / immune disorders market, 2018 - 2030 (USD Million)
  • Fig. 33 Global mesenchymal stem cell therapy by other indications market, 2018 - 2030 (USD Million)
  • Fig. 34 Regional marketplace: Key takeaways
  • Fig. 35 North America mesenchymal stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 U.S. key country dynamics
  • Fig. 37 U.S. mesenchymal stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Europe mesenchymal stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 UK key country dynamics
  • Fig. 40 UK mesenchymal stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Germany key country dynamics
  • Fig. 42 Germany mesenchymal stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Asia-Pacific mesenchymal stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Japan key country dynamics
  • Fig. 45 Japan mesenchymal stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 46 South Korea key country dynamics
  • Fig. 47 South Korea mesenchymal stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 Rest of World mesenchymal stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 49 Key company categorization
  • Fig. 50 Company market positioning
  • Fig. 51 Market participant categorization
  • Fig. 52 Strategy framework